Skip to main content

liso-cel

Generic: lisocabtagene maraleucel·Brand: Breyanzi·Code: JCAR017

liso-cel: developed by 1 company · 2 clinical trials tracked.

liso-cel evidence translation

What we can confirm

What it means

Source-backed records connect liso-cel to JUNO; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could liso-cel → JUNO affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors

Related indications

Relapsed or Refractory Follicular LymphomaLymphoma
Development Pipeline (1)
CompanyPhase
Juno Therapeutics, Inc. (JUNO)
Relapsed or Refractory Follicular Lymphoma
Phase 3
Clinical Trials (2)

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

NCT07015242·Phase 2·BMY
Recruiting

Primary endpoint: Progression-free Survival (PFS)

Interventionalopen65 targetStarted 2025-11Completion 2028-1240 sites · France, Germany, United StatesJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL)

NCT06313996·Phase 3·JUNO
Withdrawn

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizedsingle0 targetStarted 2024-03Completion 2031-10Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Frequently asked questions

Who is developing liso-cel?

liso-cel is being developed by Juno Therapeutics, Inc..

How many clinical trials involve liso-cel?

BioSniper tracks 2 clinical trials involving liso-cel.